 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
7 News |  |
- || metformin / Generic mfg.
Clinical, Journal, Combination therapy: Leucine and Sildenafil Combination Therapy Reduces Body Weight and Metformin Enhances the Effect at Low Dose: A Randomized Controlled Trial. (Pubmed Central) - Oct 1, 2021
Leu/Met/Sil 1.0 and 4.0 and Leu/Sil 4.0 reduced body weight, but Leu/Met/Sil 1.0 was associated with robust weight loss in African Americans, and individuals with BMI 30-39.9 kg/m2, especially participants with hyperinsulinemia.
- || metformin / Generic mfg., leucine/metformin/sildenafil (NS-0200) / NuSirt
Clinical, Journal: Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters. (Pubmed Central) - Jan 17, 2020
Leu/Met/Sil 1.0 and 4.0 and Leu/Sil 4.0 reduced body weight, but Leu/Met/Sil 1.0 was associated with robust weight loss in African Americans, and individuals with BMI 30-39.9 kg/m2, especially participants with hyperinsulinemia. These data support further study of NS-0200 as a therapy for obesity and associated comorbidities.
- | leucine/metformin/sildenafil (NS-0200) / NuSirt
Clinical, Journal: Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. (Pubmed Central) - Sep 18, 2019
These data support further study of NS-0200 as a therapy for obesity and associated comorbidities. These data support further evaluation of high-dose NS-0200 for treating NASH, especially in those with elevated ALT (NCT 02546609).
- | leucine/metformin/sildenafil (NS-0200) / NuSirt
Journal: Editorial: role of leucine-metformin-sildenafil combination in the treatment of nonalcoholic fatty liver disease (NAFLD). (Pubmed Central) - Jun 15, 2019
These data support further evaluation of high-dose NS-0200 for treating NASH, especially in those with elevated ALT (NCT 02546609). No abstract available
- | leucine/metformin/sildenafil (NS-0200) / NuSirt
Trial completion: The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity (clinicaltrials.gov) - Nov 27, 2018
P2, N=267, Completed, Sponsor: NuSirt Biopharma
No abstract available Enrolling by invitation --> Completed
- |||| leucine/metformin/sildenafil (NS-0200) / NuSirt
Enrollment open: The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity (clinicaltrials.gov) - Mar 22, 2018
P2, N=267, Enrolling by invitation, Sponsor: NuSirt Biopharma
Enrolling by invitation --> Completed Not yet recruiting --> Enrolling by invitation
- ||||| leucine/metformin/sildenafil (NS-0200) / NuSirt
New P2 trial: The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity (clinicaltrials.gov) - Dec 6, 2017
P2, N=250, Not yet recruiting, Sponsor: NuSirt Biopharma
- |||| leucine/metformin/sildenafil (NS-0200) / NuSirt
Trial completion: The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease (clinicaltrials.gov) - Sep 13, 2017
P2, N=91, Completed, Sponsor: NuSirt Biopharma
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- ||| leucine/metformin/sildenafil (NS-0200) / NuSirt
Enrollment closed: The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease (clinicaltrials.gov) - Jan 17, 2017
P2, N=91, Active, not recruiting, Sponsor: NuSirt Biopharma
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || leucine/metformin/sildenafil (NS-0200) / NuSirt
Trial primary completion date: The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease (clinicaltrials.gov) - Jun 28, 2016
P2, N=90, Recruiting, Sponsor: NuSirt Biopharma
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Dec 2016
- |||| leucine/metformin/sildenafil (NS-0200) / NuSirt
Enrollment open: The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease (clinicaltrials.gov) - Dec 11, 2015
P2, N=90, Recruiting, Sponsor: NuSirt Biopharma
Trial primary completion date: Aug 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- ||||| leucine/metformin/sildenafil (NS-0200) / NuSirt
New P2 trial: The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease (clinicaltrials.gov) - Sep 14, 2015
P2, N=90, Not yet recruiting, Sponsor: NuSirt Biopharma